Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Sodium Tungstate Dihydrate
2. Sodium Tungstate(vi)
3. Sodium Tungstate(vi) Dihydrate
4. Sodium Tungstate(vi), 181w-labeled
1. 13472-45-2
2. Disodium Tungstate
3. Sodium Wolframate
4. Sodium Tungstate(vi)
5. Disodium Dioxido(dioxo)tungsten
6. Tungstate, Sodium
7. Sodium Tungsten Oxide (na2wo4)
8. Tungstic Acid (h2wo4), Disodium Salt
9. Tungstic Acid, Disodium Salt
10. Disodium;dioxido(dioxo)tungsten
11. Tungstate (wo42-), Disodium, (t-4)-
12. 126752-51-0
13. 64lrh4405g
14. Disodium Wolframate
15. Sodium Tungstate (na2wo4)
16. Disodium Tungstate (na2wo4)
17. Ccris 5814
18. Sodium Tungstate (na2(wo4))
19. Disodium Tetraoxatungstate (2-)
20. Disodium Tetraoxotungstate (2-)
21. Hsdb 5057
22. Sodium Tungstate(vi) (na2wo4)
23. Einecs 236-743-4
24. Unii-64lrh4405g
25. Sodiumtungstate(vi)
26. Sodium Tungstate (vi)
27. Na2wo4
28. Disodium Tetraoxotungstate
29. Tungstate (w10o324-), Sodium (1:4)
30. Tungstate (wo42-), Disodium, (beta-4)-
31. Tungastate (wo4(2-)), Disodium, (t-4)-
32. Ec 236-743-4
33. Sodium Tetraoxotungstate(vi)
34. Disodium Tetraoxatungstate(2-)
35. Disodium Tetraoxotungstate(2-)
36. Chebi:63940
37. Sodium Tungstate(vi) [mi]
38. Akos030227979
39. Gs-3112
40. Ns00093533
41. Q418410
42. Tungstate (wo42-), Sodium (1:2), (t-4)-
43. Tungsten(4+) Ion Disodium Dihydroxide Dioxidandiide
| Molecular Weight | 293.82 g/mol |
|---|---|
| Molecular Formula | Na2O4W |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 0 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 80.3 |
| Heavy Atom Count | 7 |
| Formal Charge | 0 |
| Complexity | 62.2 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
3. 3= MODERATELY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) IS 0.5-5 G/KG, BETWEEN 1 OUNCE & 1 PINT (OR 1 POUND) FOR 70 KG PERSON (150 LB). /TUNGSTEN & ITS SALTS/
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-102
RATS...FED...100 DAYS ON DIETS /INCL SODIUM TUNGSTATE/... PRINCIPAL SITES OF DEPOSITION WERE BONE & SPLEEN WITH TRACE QUANTITIES (LESS THAN 1.0 MG %...) IN KIDNEY & LIVER, & IN SOME ANIMALS IN BLOOD, LUNG, MUSCLE & TESTES.
Friberg, L., G.R. Nordberg, and V.B. Vouk. Handbook on the Toxicology of Metals. New York: Elsevier North Holland, 1979., p. 640
...AFTER ORAL ADMIN OF SODIUM TUNGSTATE...AFTER 1 DAY, GREATEST CONCN IN SPLEEN FOLLOWED BY KIDNEY, PELT, BONE & LIVER. ...FOLLOWING ADMIN...BY GASTRIC INTUBATION IN RATS...HIGHEST CONCN IN KIDNEY FOLLOWED BY BONE & SPLEEN.
Friberg, L., G.R. Nordberg, and V.B. Vouk. Handbook on the Toxicology of Metals. New York: Elsevier North Holland, 1979., p. 640
ALMOST 1/2 OF INGESTED DOSE...OF A SOL SALT...RAPIDLY ABSORBED IN...ANIMAL MODELS... MOST OF ABSORBED TUNGSTEN...RAPIDLY EXCRETED IN URINE. SMALL AMT... RETAINED WAS TRANSFERRED IN PART FROM PLASMA TO RED BLOOD CELLS & DISTRIBUTED MAINLY TO SPLEEN, KIDNEY, & BONE. /SOL W SALT/
Friberg, L., G.R. Nordberg, and V.B. Vouk. Handbook on the Toxicology of Metals. New York: Elsevier North Holland, 1979., p. 637
FOLLOWING IV ADMIN (181)W SODIUM TUNGSTATE IN 2 BEAGLE DOGS, MOST OF ACTIVITY WAS FOUND IN PLASMA DURING 1ST 24 HR, WITH AVG PLASMA TO RED CELL RATIO 3:1, SUGGESTING BINDING OF TUNGSTEN TO CELL SURFACE RATHER THAN PENETRATION OF CELL MEMBRANE. ...SUGGESTED THAT W INCORPORATION INTO RED CELLS OCCURS @ SITES OF HEMATOPOIESIS.
Friberg, L., G.R. Nordberg, and V.B. Vouk. Handbook on the Toxicology of Metals. New York: Elsevier North Holland, 1979., p. 641
For more Absorption, Distribution and Excretion (Complete) data for SODIUM TUNGSTATE (8 total), please visit the HSDB record page.
ABOUT THIS PAGE
67
PharmaCompass offers a list of Sodium Tungstate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Tungstate manufacturer or Sodium Tungstate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Tungstate manufacturer or Sodium Tungstate supplier.
PharmaCompass also assists you with knowing the Sodium Tungstate API Price utilized in the formulation of products. Sodium Tungstate API Price is not always fixed or binding as the Sodium Tungstate Price is obtained through a variety of data sources. The Sodium Tungstate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 13472-45-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 13472-45-2, including repackagers and relabelers. The FDA regulates 13472-45-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 13472-45-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 13472-45-2 supplier is an individual or a company that provides 13472-45-2 active pharmaceutical ingredient (API) or 13472-45-2 finished formulations upon request. The 13472-45-2 suppliers may include 13472-45-2 API manufacturers, exporters, distributors and traders.
13472-45-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 13472-45-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 13472-45-2 GMP manufacturer or 13472-45-2 GMP API supplier for your needs.
A 13472-45-2 CoA (Certificate of Analysis) is a formal document that attests to 13472-45-2's compliance with 13472-45-2 specifications and serves as a tool for batch-level quality control.
13472-45-2 CoA mostly includes findings from lab analyses of a specific batch. For each 13472-45-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
13472-45-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (13472-45-2 EP), 13472-45-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (13472-45-2 USP).
